Elypta

Elypta develops a metabolism-based liquid biopsy platform for cancer detection, measuring the GAGome (glycosaminoglycan biomarkers of tumor metabolism) and using machine learning to detect cancer signatures noninvasively. The company's MIRAM Kit enables analysis of urine and blood samples, with clinical studies showing game-changing potential in kidney cancer follow-up and the ability to predict risk of developing any-type cancer with a simple urine test. Elypta is a main partner in PREDI-LYNCH, a pan-European hereditary multi-cancer screening project that received 13.6 million euros in EU funding. Founded in 2017 and headquartered in Stockholm, Sweden, the company has raised approximately $27.9M in Series A funding. Elypta differentiates itself through its novel metabolism-based approach to liquid biopsy, using system biomarkers rather than tumor-derived DNA, enabling earlier cancer detection and recurrence monitoring across multiple cancer types.